Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

In vivo targeting of neoepitopes induced by arginine deprivation in cancer

Obiettivo

More than five decades have passed since asparagine depletion was developed into a successful therapy for childhood leukaemia. However, attempts to extend this treatment to other cancer types and amino acids were unsuccessful due to limited clinical benefit.

One of the most promising approaches for amino acid deprivation therapy leveraged the fact that most solid tumours (~70%) suppress intracellular arginine production, thereby becoming auxotrophic for arginine. However, although arginine deprivation monotherapies are well-tolerated and have been found to deplete arginine effectively, they have failed to benefit overall patient survival due to the development of treatment tolerance. Combinatorial therapies of arginine deprivation with chemotherapy and immunotherapy provided little advance.

Neoepitopes, defined as HLA-bound peptides derived from inducible tumour-specific aberrant proteins, offer an exciting new opportunity to overcome tolerance mechanisms. Using immunopeptidomics, we identified common neoepitopes emerging from arginine-deprived cancer cells. We further developed, validated, and characterized neoepitope-targeting T-cell receptors (TCRs) in vitro. We believe that these TCRs could be used to eliminate tumour cells before resistance to arginine deprivation emerges. However, due to the temporal expression of such neoepitopes, in vivo targeting remains a significant challenge, and a proof-of-concept experiment showing their in vivo utility is lacking.

This proposal aims to provide proof-of-concept mouse experiments for the in vivo application of combining arginine deprivation therapy with adoptive TCR T cell therapy targeting a shared and broadly expressed neoepitope induced by arginine deprivation. Ultimately, this innovative strategy aims to enhance the therapeutic efficacy of arginine deprivation and improve patient outcomes, offering a transformative approach to combat therapy resistance and enhance survival rates.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2026-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Contributo netto dell'UE
€ 150 000,00
Costo totale
Nessun dato

Beneficiari (1)